King Willem-Alexander of the Netherlands opens the new headquarters of Applikon Biotechnology

Delft, (PresseBox) - On Wednesday December 4th the new headquarters of Applikon Biotechnology in Delft, the Netherlands will be opened by His Majesty King Willem-Alexander of the Netherlands. The grand opening will be attended by (inter)national customers, business relations,(inter)national officials, scientific relations and the entire team of the Applikon Biotechnology in the Netherlands.

The new production facility has been operational for several months and the festivities planned on December 4th are to celebrate this achievement and to officially mark this further step in the development and growth of the company. Arthur Oudshoorn, Managing Director of Applikon Biotechnology, and his dedicated team are proud and happy with these new premises which house the state-of-the-art warehouse and production facilities, R&D laboratory space and offices for approximately 100 employees.

In this new facility, Applikon Biotechnology is now able to provide a complete range of bioreactor systems ranging from micro liter research volumes up to 15.000 liter production systems for pharmaceutical and biotechnological applications.

Applikon Biotechnology B.V

Applikon Biotechnology BV (Delft, Netherlands) is a privately owned leading supplier of bioreactor systems for the pharmaceutical and the biotechnological market. We specialize in novel technologies in cultivation systems, measurement and control for the biopharmaceutical industry. In the past years, Applikon Biotechnology has built up a broad portfolio of unique bioprocessing devices for both cell culture and microbial cultivation, and this has considerably set us apart from the competition.

www.applikon-biotechnology.com

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.